Navigation Links
Regado Biosciences Announces First Patient Enrolled in RADAR (Phase 2b) Study of REG1 Anticoagulation System
Date:9/9/2009

BASKING RIDGE, N.J., Sept. 9 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, announced that on September 8, 2009 enrollment of the first patient in a Phase 2b, randomized, partially-blinded, multi-center, active-controlled, dose-ranging study of its lead product candidate, the REG1 anticoagulation system (REG1) was achieved. REG1 comprises the selective factor IXa inhibitor, RB006, and its specific active control agent, RB007. The trial, called RADAR, will assess the safety, efficacy, and pharmacodynamics of REG1 compared to unfractionated heparin or low molecular weight heparin in subjects with acute coronary syndromes (ACS). Regado recently successfully completed a phase 2a study of REG1 in stable coronary artery disease patients undergoing elective PCI.

The primary objectives of RADAR will be to determine the clinically acceptable dose range of the specific active control agent, RB007, which can be used to reliably partially or totally reverse the anticoagulant effect of RB006 while reducing bleeding in comparison to heparin, and to determine the pharmacodynamics of the REG1 anticoagulation system in subjects intended for cardiac catheterization within 24 hours who are admitted for ACS-unstable angina and myocardial infarction without ST-segment elevation (UA/NSTEMI).

RADAR, led by principal investigator John H. Alexander, MD, MHS, FACC of Duke University, will enroll 800 subjects at approximately 75 centers around the world. Participating countries include USA, Canada, Poland, France, Germany, Netherlands and Belgium. More information about RADAR can be found at www.clinicaltrials.gov. The identifier for this trial is NCT00932100.

"We are very excited to report the first patient being en
'/>"/>

SOURCE Regado Biosciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Regado Biosciences to Present at 19th Annual Piper Jaffray Health Care Conference
2. Alexander R. Giaquinto, Ph.D., Joins Regado Biosciences as Senior Vice President of Regulatory Affairs and Quality Assurance
3. Regado Biosciences to Present at the 2009 Wharton Healthcare Business Conference
4. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
5. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
6. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
7. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
8. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
9. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
10. Anaptys Biosciences Raises Over $33 Million in Series B Financing
11. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Texas (PRWEB) May 28, 2015 Park Cities ... Group Dog Training class starting Saturday, June 6th ... the courtyard of 5831 McCommas Blvd in Dallas, with a ... classes will run for five weeks, with no class being ... the class is $135. , In this Intermediate-to-Advanced level class, ...
(Date:5/28/2015)... Three years ago, Dr. Jeffrey Gosin announced ... Vascular & Vein Center! Dr. Gosin’s center is ... is his mission to provide the highest quality care in ... Dr. Jeffrey Gosin is Board Certified in Surgery and Vascular ... and Jefferson Medical College. He completed a General Surgery residency ...
(Date:5/28/2015)... May 28, 2015 AMVETS leaders this ... prize winner Robert Davis of Newark, Del. AMVETS National ... him on winning the $10,000 sweepstakes grand prize. , ... 100,000 entries from around the country for prizes ranging ... took place on May 21 at the AMVETS National ...
(Date:5/28/2015)... Medelis, Inc., a specialty oncology CRO , ... the role of president. , “ Bill Taaffe has ... said Larry Flanagan, Medelis’ CEO and co-founder. “He will be ... phase of growth.” , Taaffe joined ICON’s U.S. clinical ... to over 4,500 employees, achieving 12 consecutive years of growth ...
(Date:5/28/2015)... 28, 2015 ISMETT , a leading ... boosted the Sicilian economy by €132.5 million in expenditure in ... of more than €73 million by retaining patients who otherwise ... a new study by the Battelle Memorial Institute. At the ... training and advanced health care management that is transforming Sicily ...
Breaking Medicine News(10 mins):Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 2Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 3Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 2Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 3Health News:AMVETS Announces Summer Sweepstakes Winners 2Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2Health News:UPMC-Managed Transplant Hospital Drives Major Economic Benefits for Sicily, Study Finds 2Health News:UPMC-Managed Transplant Hospital Drives Major Economic Benefits for Sicily, Study Finds 3
... Holohan HealthDay Reporter , WEDNESDAY, Jan. 5 (HealthDay ... of chickenpox-related hospitalizations in the United States for the first ... And a second study has found that the ... Centers for Disease Control and Prevention in 2006, may offer ...
... doses of the varicella, or chickenpox, vaccine provide excellent protection ... severe disease. To be published in the February 1 issue ... support the two-dose vaccine regimen recommended in the United States ... study online.) The Centers for Disease Control and Prevention ...
... HealthDay Reporter , TUESDAY, Jan. 4 (HealthDay News) -- Up ... an increase that translates into many fewer injuries and deaths ... the first state law requiring seat belts was passed in ... But now, according to the U.S. Centers for Disease Control ...
... HealthDay Reporter , TUESDAY, Jan. 4 (HealthDay News) -- ... of the drug Avastin to treat breast cancer, a new ... odds of congestive heart failure in these patients. The ... Clinical Oncology , included almost 4,000 patients and found a ...
... DURHAM, N.C. A tiny light source and sensors at ... way to identify pre-cancerous cells in the lining of the ... successfully tested on patients during a clinical trial at the ... the promise of being a less invasive method for testing ...
... there is often concern about possible effects on the ... birth defects (thalidomide being a notorious example), and others ... about most drugs, level of risk. Researchers in the ... preclinical model for predicting a drug,s teratogenicity (tendency to ...
Cached Medicine News:Health News:Chickenpox Vaccine Cuts Hospitalization Rates: Study 2Health News:Chickenpox Vaccine Cuts Hospitalization Rates: Study 3Health News:Chickenpox Vaccine Cuts Hospitalization Rates: Study 4Health News:Study confirms 2 vaccine doses protect children from chickenpox 2Health News:Six Out of 7 Drivers Use Seat Belts: CDC 2Health News:Six Out of 7 Drivers Use Seat Belts: CDC 3Health News:More Evidence Links Avastin to Heart Failure in Breast Cancer Patients 2Health News:More Evidence Links Avastin to Heart Failure in Breast Cancer Patients 3Health News:Detecting esophageal cancer with light 2Health News:Model predicts a drug's likelihood of causing birth defects 2
(Date:5/28/2015)... , May 28, 2015 KaloBios Pharmaceuticals, ... of Ronald A. Martell , to the position ... member of the KaloBios Board of Directors. In this ... senior management team to refine and execute on the ... antibody company developing therapeutics for orphan oncology indications with ...
(Date:5/28/2015)... May 28, 2015  CytomX, a biotechnology company developing ... that Sean McCarthy , D. Phil., chief executive ... Global Healthcare Conference in New York ... 2, 2015. Dr. McCarthy will provide an overview of ... and Probody drug conjugate programs. About CytomX ...
(Date:5/28/2015)... DIEGO and CAMBRIDGE, Mass., May 28, 2015 ... is investigating whether certain officers and ... fiduciary duties to shareholders.  Eleven Biotherapeutics is a ... and development of protein therapeutics to treat eye ... .   View this press ...
Breaking Medicine Technology:KaloBios Appoints Ronald A. Martell Executive Chairman 2KaloBios Appoints Ronald A. Martell Executive Chairman 3KaloBios Appoints Ronald A. Martell Executive Chairman 4KaloBios Appoints Ronald A. Martell Executive Chairman 5Robbins Arroyo LLP Is Investigating the Officers and Directors of Eleven Biotherapeutics, Inc. (EBIO) on Behalf of Shareholders 2
... Lexicon Pharmaceuticals, Inc. (Nasdaq: ... treatments for human disease, announced today that Arthur ... executive officer, will present at the Morgan Stanley Global ... 14, 2011 at 9:10 a.m. Eastern Time.  Dr. Sands ...
... Sept. 5, 2011 Reportlinker.com ... research report is available in ... Facial Aesthetics (Botox, Dermal Fillers, ... Competitive Landscape and Market Forecasts ...
Cached Medicine Technology:Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference 2Facial Aesthetics (Botox, Dermal Fillers, Collagen) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 2Facial Aesthetics (Botox, Dermal Fillers, Collagen) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 3Facial Aesthetics (Botox, Dermal Fillers, Collagen) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 4Facial Aesthetics (Botox, Dermal Fillers, Collagen) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 5Facial Aesthetics (Botox, Dermal Fillers, Collagen) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 6Facial Aesthetics (Botox, Dermal Fillers, Collagen) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 7Facial Aesthetics (Botox, Dermal Fillers, Collagen) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 8Facial Aesthetics (Botox, Dermal Fillers, Collagen) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 9
... The Techne TC-512 has a graphical touch ... your experiments at the "touch of a ... Wide linear gradient, Touch Screen, Graphical Display, ... Performance, Versatile Block Format, Intuitive Programmin, Free ...
... Techne TC412 is a high performance, high sample ... Features & Benefits include: Flexible block format, ... 8 peltiers, PC networking. Includes a four ... 32 Techne cyclers can be connected and run ...
... a compact design for personal use, yet is able ... up to 32 samples simultaneously. It contains a heating ... to add mineral oil to prevent evaporation of the ... and up to 15 steps can be freely connected ...
... cycler is the smallest footprint two-bay thermal ... ever before. The Disciple instrument ... communications to a computer using a remote ... thermal cycler contains the latest in power ...
Medicine Products: